By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting originating in Seoul, South Korea, by NewsRx journalists, research stated, "It is important to simultaneously induce strong cell death and antitumor immunity in cancer patients for successful cancer treatment. Here, we investigated the cytotoxic and phenotypic modulation effects of the combination of ANT2 shRNA and human sodium iodide symporter (hNIS) radioiodine gene therapy in vitro and in vivo and visualized the antitumor effects in an immunocompromised mouse colon cancer model."
The news reporters obtained a quote from the research from the Seoul National University College of Medicine, "A mouse colon cancer cell line co-expressing hNIS and the luciferase gene (CT26/hNIS-Fluc, named CT26/NF) was established. CT26/NF cells and tumor-bearing mice were treated with HBSS, scramble, ANT2 shRNA, I-131, and ANT2 shRNA + I-131. The apoptotic rates (%) and MHC class I and Fas gene expression levels were determined in treated CT26/NF cells using flow cytometry. Concurrently, the level of caspase-3 activation was determined in treated cells in vitro. For in vivo therapy, tumor-bearing mice were treated with scramble, ANT2 shRNA, I-131, and the combination therapy, and the anti-tumor effects were monitored using bioluminescence. The killing activity of cytotoxic T cells (CTLs) was measured with a lactate dehydrogenase (LDH) assay. For the in vitro experiments, the combination of ANT2 shRNA and I-131 resulted in a higher apoptotic cell death rate compared with ANT2 shRNA or I-131 alone, and the levels of MHC class I and Fas-expressing cancer cells were highest in the cells receiving combination treatment, while single treatment modestly increased the level of MHC class I and Fas gene expression. The combination of ANT2 shRNA and I-131 resulted in a higher caspase-3 activation than single treatments. Interestingly, in vivo combination treatment led to increased gene expression of MHC class I and Fas than the respective mono-therapies; furthermore, bioluminescence showed increased antitumor effects after combination treatment than monotherapies. The LDH assay revealed that the CTL killing activity against CT26/NF cells was most effective after combination therapy. Increased cell death and phenotypic modulation of cancer cells in vitro and in vivo were achieved simultaneously after combination therapy with ANT2 shRNA and I-131, and this combination therapy induced remarkable antitumor outcomes through improvements in CTL immunity against CT26/NF."
According to the news reporters, the research concluded: "Our results suggest that combination therapy can be used as a new therapeutic strategy for cancer patients who show resistance to single therapy such as radiation or immunotherapy."
For more information on this research see: The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: combination treatment with ANT2 shRNA and I-131. Bmc Cancer, 2013;13():143. Bmc Cancer can be contacted at: Biomed Central LTD, Middlesex House, 34-42 Cleveland St, London W1T 4LB, England. (BioMed Central - www.biomedcentral.com/; Bmc Cancer - www.biomedcentral.com/bmccancer/)
Our news correspondents report that additional information may be obtained by contacting Y. Choi, Dept. of Pathology, Seoul National University College of Medicine, Seoul, South Korea. Additional authors for this research include H.W. Lee, J. Lee and Y.H Jeon (see also Biotechnology).
The publisher of the journal Bmc Cancer can be contacted at: Biomed Central LTD, Middlesex House, 34-42 Cleveland St, London W1T 4LB, England.
Keywords for this news article include: Asia, Biotechnology, Seoul, Oncology, Treatment, South Korea, Therapeutics, Immunotherapy, Bioengineering, Immunomodulation, Cancer Gene Therapy.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC